dihydroergotamine nasal investigational Trudhesa
Selected indexed studies
- Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study. (CNS Drugs, 2024) [PMID:39373843]
- Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine. (Headache, 2024) [PMID:38800847]
- Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open-label ASCEND acute migraine study. (Headache, 2026) [PMID:41186275]
_Worker-drafted node — pending editorial review._
Connections
dihydroergotamine nasal investigational Trudhesa is a side effect of
Sources
- Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study. (2024) pubmed
- Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine. (2024) pubmed
- Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open-label ASCEND acute migraine study. (2026) pubmed
- STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD(®) ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. (2021) pubmed